SCHEMBL4280

SCHEMBL4280

c1ccc(C2CCCNC2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SLC18A3 Q16572 1/20 0.59
SIGMAR1 Q99720 1/20 0.59
DRD2 P14416 1/20 0.59
DRD3 P35462 1/20 0.59
KCNH2 Q12809 2/20 0.53
HTR2A P28223 1/20 0.53
HTR2C P28335 1/20 0.53
HTR3A P46098 1/20 0.52
KDM1A O60341 1/20 0.51
MAOB P27338 1/20 0.51
JAK3 P52333 1/20 0.50
CYP2D6 P10635 1/20 0.49
SLC6A2 P23975 1/20 0.49
SLC6A4 P31645 1/20 0.49
SLC6A3 Q01959 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL383031 1.00 SLC18A3 (0.59) SLC18A3SIGMAR1DRD2DRD3KCNH2
Benzene SCHEMBL28198364 1.00 SLC18A3 (0.59) SLC18A3SIGMAR1DRD2DRD3KCNH2
SCHEMBL381572 1.00 SLC18A3 (0.59) SLC18A3SIGMAR1DRD2DRD3KCNH2
Hydrochloric Acid SCHEMBL1765272 0.98 DRD2 (0.57) SLC18A3SIGMAR1DRD2DRD3KCNH2
Hydrochloric Acid SCHEMBL31233227 0.98 DRD2 (0.57) SLC18A3SIGMAR1DRD2DRD3KCNH2
SCHEMBL3701789 0.94 SLC18A3 (0.57) SLC18A3SIGMAR1DRD2DRD3KCNH2
Hydrochloric Acid SCHEMBL3689510 0.92 SLC18A3 (0.55) SLC18A3SIGMAR1DRD2DRD3KCNH2
SCHEMBL28296875 0.91 DRD2 (0.51) SLC18A3SIGMAR1DRD2DRD3KCNH2
Pyridine SCHEMBL11331327 0.89 DRD2 (0.50) SLC18A3SIGMAR1DRD2DRD3KCNH2
SCHEMBL495697 0.89 SLC18A3 (0.75) SLC18A3SIGMAR1HTR3AJAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 725 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024079351-A1 NOVEL PIPERAZINE-BASED SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS GENECODE (EE) 2024-04-18 WO claimed
US-20230010299-A1 HETEROCYCLIC TRPML1 AGONISTS LIBRA THERAPEUTICS, INC. 2023-01-12 US claimed
EP-4058145-A1 HETEROCYCLIC TRPML1 AGONISTS Libra Therapeutics, Inc. (US) 2022-09-21 EP claimed
WO-2021094974-A1 HETEROCYCLIC TRPML1 AGONISTS LIBRA THERAPEUTICS, INC. (US) 2021-05-20 WO claimed
EP-3821947-A1 HETEROCYCLIC TRPML1 AGONISTS Libra Therapeutics, Inc. (US) 2021-05-19 EP claimed
EP-2807171-B1 HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE NOVARTIS AG (CH) 2020-08-12 EP claimed
CN-109810047-A (R) synthetic method of the chiral intermediate of -3- Phenylpiperidine or/and (S) -3- Phenylpiperidine and Ni Lapani 上海博邦医药科技有限公司 2019-05-28 CN claimed
CN-106146388-B A kind of 3- phenyl-piperidines analog derivative synthetic method 山东理工大学 2018-12-04 CN claimed
CN-108203404-A (R) synthetic method of -3- Phenylpiperidines or/and the chiral intermediate of (S) -3- Phenylpiperidines and Ni Lapani 上海博邦医药科技有限公司 2018-06-26 CN claimed
CN-106146388-A A kind of 3 phenylpiperidine derivative synthesizing process 山东理工大学 2016-11-23 CN claimed
CN-104470930-A Heterocyclic compounds and methods for their use SPINIFEX PHARM PTY LTD 2015-03-25 CN claimed
US-7790898-B2 Substituted 3-phenylpiperidine compounds, their preparation and use GRUENENTHAL GMBH (DE) 2010-09-07 US claimed
US-20070173533-A1 Substituted 3-phenylpiperidine compounds, their preparation and use GRUENENTHAL GMBH (DE) 2007-07-26 US claimed
EP-1771417-A1 SUBSTITUTED 3-PHENYLPIPERIDINE DERIVATIVES Grünenthal GmbH (DE) 2007-04-11 EP claimed
WO-2006010577-A1 SUBSTITUTED 3-PHENYLPIPERIDINE DERIVATIVES Grünenthal GmbH (DE) 2006-02-02 WO claimed
EP-0188805-B1 1,3-DITHIOLE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 1989-09-06 EP claimed
EP-0188805-A1 1,3-Dithiole derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 1986-07-30 EP claimed
CN-116546990-B CD73 inhibitor and pharmaceutical application thereof RISEN (SUZHOU) PHARMA TECH Co.,Ltd. (CN) 2026-05-26 CN disclosed
US-4007191-A ANTIDEPRESSANT E. R. SQUIBB & SONS, INC. (US) 1977-02-08 US disclosed
US-3935227-A ANTIDEPRESSANTS, ANTIANXIETY, ANTIINFLAMMATORY AGENTS E. R. SQUIBB & SONS, INC. (US) 1976-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230010299-A1 HETEROCYCLIC TRPML1 AGONISTS TRPM7, TRPM2, TRPM5 SLC18A3 477/4885SIGMAR1 1483/4885DRD2 3911/4885
US-20070173533-A1 Substituted 3-phenylpiperidine compounds, their preparation and use OPRK1, OPRD1, OPRL1 SLC18A3 2270/4885SIGMAR1 19/4885DRD2 103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.